Rexam to expand La Verpillière production site in France
New building will house 2400m² clean rooms devoted to produce the sub-sets of insulin injection pens. Rexam has been supplying the sub-sets of insulin injection pen to Lilly
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
The family of anti-inflammatory Phylomer peptides including PYC35, PYC36, PYC38 and PYC98, which targets the AP-1 pathway, have demonstrated efficacy in multiple preclinical models for stroke, traumatic brain